Skip to content

Cumberland Pharmaceuticals Inc.: 10-Q filed 2023-11-13

What Cumberland Pharmaceuticals Inc. reported in its quarterly report filed 2023-11-13 (fiscal Q3 2023): 41 published measures, 117 facts as tagged in accession 0001628280-23-038418.

This filing

Form
10-Q (quarterly report)
Filed
2023-11-13
Fiscal period
fiscal Q3 2023
Accession
0001628280-23-038418 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cumberland Pharmaceuticals Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-09-3087,750,944USD
At 2022-12-3192,925,158USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-09-3052,095,386USD
At 2022-12-3156,951,152USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-09-3035,991,549USD
At 2022-12-3136,266,132USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-09-3018,507,965USD
At 2022-12-3119,757,970USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-1,049,298USD92
2023-01-01 to 2023-09-3015,086USD273
2022-07-01 to 2022-09-30-408,639USD92
2022-01-01 to 2022-09-30-3,129,512USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-09-305,053,700USD273
2022-01-01 to 2022-09-304,815,365USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-01-01 to 2023-09-30232,595USD273
2022-01-01 to 2022-09-30255,676USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2023-07-01 to 2023-09-3010,085,926USD92
2023-01-01 to 2023-09-3030,199,441USD273
2022-07-01 to 2022-09-3011,413,072USD92
2022-01-01 to 2022-09-3032,887,269USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-5,937,371USD273
2022-01-01 to 2022-09-30719,041USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-366,334USD273
2022-01-01 to 2022-09-30-13,033,684USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-09-30-11,193,755USD
At 2022-12-31-11,208,841USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-07-01 to 2023-09-3014,277,229shares92
2023-01-01 to 2023-09-3014,343,560shares273
2022-07-01 to 2022-09-3014,477,478shares92
2022-01-01 to 2022-09-3014,618,975shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-07-01 to 2023-09-3014,277,229shares92
2023-01-01 to 2023-09-3014,521,600shares273
2022-07-01 to 2022-09-3014,477,478shares92
2022-01-01 to 2022-09-3014,618,975shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-07-01 to 2023-09-306,938USD92
2023-01-01 to 2023-09-3020,813USD273
2022-07-01 to 2022-09-306,900USD92
2022-01-01 to 2022-09-3020,700USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-09-30377,439USD
At 2022-12-31284,039USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-09-30271,146USD273
2022-01-01 to 2022-09-30320,598USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-1,866,603USD92
2023-01-01 to 2023-09-30-3,375,422USD273
2022-07-01 to 2022-09-30-288,588USD92
2022-01-01 to 2022-09-30-3,427,125USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-09-3041,769,797USD
At 2022-12-3145,870,210USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-07-01 to 2023-09-30110,081USD92
2023-01-01 to 2023-09-30489,069USD273
2022-07-01 to 2022-09-30149,340USD92
2022-01-01 to 2022-09-30406,539USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-09-3027,328,270USD
At 2022-12-3128,579,832USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-09-3010,818,045USD
At 2022-12-3110,819,011USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2023-09-30914,000USD
At 2022-12-31914,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-09-3027,121,070USD
At 2022-12-3130,590,678USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-09-3012,620,120USD
At 2022-12-3113,163,681USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2023-01-01 to 2023-09-30551,563USD273
2022-01-01 to 2022-09-30863,383USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-09-308,670,548USD
At 2022-12-319,863,581USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-07-01 to 2023-09-301,924,768USD92
2023-01-01 to 2023-09-304,569,476USD273
2022-07-01 to 2022-09-301,714,254USD92
2022-01-01 to 2022-09-305,283,083USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-09-3014,217,926shares
At 2022-12-3114,366,616shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-09-3018,507,965USD
At 2022-12-3119,757,970USD
At 2022-09-3019,541,538USD
At 2021-12-3127,040,816USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2023-09-3035,655,558USD
At 2023-06-3036,836,902USD
At 2023-03-3136,048,487USD
At 2022-12-3135,974,006USD
At 2022-09-3038,890,722USD
At 2022-06-3039,204,292USD
At 2022-03-3140,793,403USD
At 2021-12-3142,601,978USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-09-306,711,155USD
At 2022-12-315,218,403USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-09-305,723,188USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-09-302,555,638USD
At 2022-12-312,520,661USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-09-306,455,091USD
At 2022-12-317,585,019USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-1,056,281USD92
2023-01-01 to 2023-09-30-7,966USD273
2022-07-01 to 2022-09-30-416,326USD92
2022-01-01 to 2022-09-30-3,169,625USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2023-07-01 to 2023-09-30-1,063,219USD92
2023-01-01 to 2023-09-30-28,779USD273
2023-04-01 to 2023-06-30862,154USD91
2023-01-01 to 2023-03-31172,286USD90
2022-07-01 to 2022-09-30-423,226USD92
2022-01-01 to 2022-09-30-3,190,325USD273
2022-04-01 to 2022-06-30-1,364,666USD91
2022-01-01 to 2022-03-31-1,402,433USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-07-01 to 2023-09-302,343,855USD92
2023-01-01 to 2023-09-307,212,731USD273
2022-07-01 to 2022-09-302,166,118USD92
2022-01-01 to 2022-09-306,672,442USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2023-01-01 to 2023-09-303,702,687USD273
2022-01-01 to 2022-09-304,816,630USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2023-07-01 to 2023-09-301,175,174USD92
2023-01-01 to 2023-09-303,563,493USD273
2022-07-01 to 2022-09-301,486,448USD92
2022-01-01 to 2022-09-304,609,146USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-890,361USD273
2022-01-01 to 2022-09-308,184,656USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-09-30-418,355USD273
2022-01-01 to 2022-09-30-1,338,881USD273

Inspect the source

Entity
Cumberland Pharmaceuticals Inc. / CIK 0001087294
Captured
2026-09-20T05:21:29.619Z
SEC response SHA-256
b37ed2fef35db1cde0c40b2233eb97cf370fc96d41a5c7d61b6a5a76a296e4a0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001087294.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))